Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF)

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
371
Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Spearheading the Future of Healthcare Through Technology, Innovation and Support for Pharmacists

- Avricore seeks to build the world’s largest network of diagnostic centres in pharmacy.
- Through its flagship platform, HealthTab(TM), the company is simplifying patients’ lives through easy access to point-of-care testing
- Through innovation, technology and partnering with key players in the industry, Avricore is allowing easy access to critical health information for patients and doing so in a convenient way for them. This, it believes, is the future of healthcare

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator committed to acquiring and developing early-stage technologies that seek to grow and push pharmacy forward. Since its inception, this Vancouver-based enterprise has stayed true to its mission to become the world’s largest health data company. This is evidenced by its move to innovate and leverage specific point-of-care technologies within its community of pharmacies.

Avricore’s flagship platform, HealthTab(TM), impacts the healthcare sector mainly by simplifying patients’ lives with easy access to point-of-care testing. With HealthTab, Avricore can offer pharmacies complete turnkey and point-of-care rapid testing systems covering both software and hardware (https://nnw.fm/WjIzc). Consequently, customers can quickly and conveniently check for markets associated with conditions such as heart disease, diabetes or any other conditions, with a simple finger-prick blood test and under the guidance of a pharmacist.

“HealthTab is a way for anybody to get access to important health information in a way that’s convenient for them, and at a time that’s convenient for them,” noted Rodger Seccombe, the Chief Technology Officer (“CTO”) at Avricore (https://nnw.fm/3oXt7).

It is one thing to have the technology and expertise to test patients quickly, but it is a whole other thing to get it to the intended patients. This is why Avricore has resorted to partnerships in a decentralization move that facilitates its growth and makes its technology and services accessible to as many people as possible.

So far in 2021, Avricore has secured a distribution agreement with Abbott Canada, the first of its type for a health-data company. Avricore also entered into a master agreement with Shoppers Drug Mart in Canada, giving its service access to over 1,300 stores, a move that so far is proving successful. With the point-of-care diagnostics market projected to grow to $50.6 billion by 2025, Avricore is positioning itself to grow with it and arguably become a leader in the industry (https://nnw.fm/3oXt7).

Currently, Avricore earns its revenue from data collection, equipment leasing, API integration, the sale of consumables associated with testing, along with screening tests. As time progresses, and with the investments and partnerships it is forging along the way, the company looks forward to forming an in-pharmacy network. This would allow it to secure steady revenues and collect real-world data that would enable researchers to quickly and efficiently examine health data trends, eventually transforming that into another source of income.

The COVID-19 pandemic presented a massive growth for Avricore’s market opportunity. For starters, the public learned the positive impacts of early detection and rapid testing. Avricore’s Chief Executive Officer (“CEO”), Hector Bremner, acknowledged this opportunity, even citing rapid testing and early detection as “The future of pharmacy (https://nnw.fm/3oXt7).” With different companies also recognizing this opportunity, Avricore has managed to stay one step ahead by bringing its services closer to the people with its pharmacies.

“Yes, you need good instruments, but you need a whole system around that instrument,” noted Seccombe. “That’s where we’ve come in and developed a real out-of-box solution that works for pharmacies (https://nnw.fm/3oXt7).”

All the milestones achieved by Avricore throughout 2021, including the Ellerca Health Partnership, HealthTab rollout and the Shoppers Drug Mart agreement, among others, are representative of an enterprise that is constantly pushing the envelope in the healthcare sector. Avricore is staying true to its mission, and because of this, it is defining the future of healthcare.

To learn more about the company, please visit www.AvricoreHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://nnw.fm/AVCRF

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Avricore Health Inc. (AVCRF) Stock Research Links

AVCRF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 10

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Microbot Medical Secures $13 Million in Recent Offering

Updated Category News Views 92

Microbot Medical Makes Strategic Move with $13 Million Offering Microbot Medical Inc. (NASDAQ: MBOT) has recently taken an important step to elevate its operations by entering into definitive agreements to sell 6,103,289 shares of its common stock at a price of $2.13 per share. This registered direct offering, priced at-the-market under Nasdaq rules, underscores the...

Continue Reading
Evolv Technologies Faces Class Action Lawsuit: Know Your Rights

Updated Category News Views 651

Understanding the Evolv Technologies Holdings Class Action Recent developments have raised significant concerns among shareholders of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV). A class action lawsuit is currently in progress, prompting investors to scrutinize the implications of false statements made by the company. The allegations revolve around misleading...

Continue Reading
Rhino Rescue Unveils Innovative First Aid Kits for Adventurers

Updated Category News Views 117

Rhino Rescue Launches Innovative Products for Outdoor Safety Rhino Rescue has made a remarkable stride in enhancing outdoor safety with its new lineup of first aid kits targeted towards adventurers and everyday users alike. The release of the Rhino Rescue Mini First Aid Kit, along with home and camping-specific options, marks an exciting development in the company’s...

Continue Reading
RUSH's 2026 Tour: Celebrating Legacy and New Beginnings

Updated Category News Views 258

RUSH's 2026 Tour: A Celebration of Music and Legacy Geddy Lee and Alex Lifeson are set to celebrate over 50 years of RUSH's musical journey as they announce a special headline tour for 2026, named the Fifty Something Tour. This tour not only commemorates the incredible music and legacy of RUSH, but also pays tribute to their late drummer and lyricist Neil Peart, whose...

Continue Reading
BioSyent Inc. Announces Quarterly Dividend for Shareholders

Updated Category News Views 132

BioSyent Inc. Announces Quarterly Dividend for Shareholders MISSISSAUGA, Ontario — BioSyent Inc. (TSX Venture: RX) is thrilled to communicate that its Board of Directors has approved a quarterly dividend of $0.05 per common share. This dividend will be paid in Canadian Dollars on a specified date to shareholders who are on record, enhancing the company's ongoing...

Continue Reading